NEW YORK and LONDON, Oct. 8,
2019 /PRNewswire/ -- Health Sciences Acquisitions
Corporation ("HSAC," NASDAQ: HSAC), a special purpose acquisition
company sponsored by RTW Investments, and Immunovant Sciences Ltd.
("Immunovant"), a clinical-stage biopharmaceutical company focused
on enabling normal lives for patients with autoimmune diseases,
today announced that they will host a joint conference call to
discuss their planned merger. The conference call will take place
on Friday, October 11, at
8:30am EDT. Following prepared
remarks, the call will include a question-and-answer session for
the investment community.
To access the webcast, please visit Immunovant's website at
www.immunovant.com. Participants may also dial in using the numbers
provided below. When prompted, participants should request to join
the "HSAC and Immunovant Conference Call."
Toll Free: 1-877-407-9039
Toll/International: 1-201-689-8470
Following the webcast, an archived version of the call will be
available for 6 months at www.immunovant.com.
About Immunovant
Immunovant, a member of the Roivant family of companies, is a
clinical-stage biopharmaceutical company focused on enabling normal
lives for patients with autoimmune diseases. Immunovant is
developing IMVT-1401, a novel, fully human anti-FcRn monoclonal
antibody, as a subcutaneous injection for the treatment of
autoimmune diseases mediated by pathogenic IgG antibodies. For
further information about Immunovant, please visit
www.immunovant.com.
About Roivant
Roivant Sciences aims to improve health by rapidly delivering
innovative medicines and technologies to patients. Roivant does
this by building Vants – nimble, entrepreneurial biotech, and
healthcare technology companies with a unique approach to sourcing
talent, aligning incentives, and deploying technology to drive
greater efficiency in R&D and commercialization. For further
information about Roivant, please visit www.roivant.com.
About Health Sciences Acquisitions Corporation
HSAC is a Delaware company
established for the purpose of entering into a merger, share
exchange, asset acquisition, share purchase, recapitalization,
reorganization or similar business combination with one or more
businesses or entities. On May 14,
2019, HSAC raised $115 million
to achieve this goal. As of June 30,
2019, there was approximately $115.3
million in HSAC's trust account. HSAC is sponsored by RTW
Investments.
About RTW Investments
RTW Investments, LP ("RTW") is a New
York-based investment firm that focuses on identifying
transformational and disruptive innovations in biopharmaceutical
and medical technologies. As a leading partner of industry and
academia, RTW utilizes deep scientific expertise and a rigorous and
comprehensive process to support emerging medical therapies. For
further information about RTW, please visit www.rtwfunds.com.
Participants in the Solicitation
Immunovant Sciences Ltd. ("Immunovant"), Health Sciences
Acquisitions Corporation ("HSAC"), and their respective directors,
executive officers and employees and other persons may be deemed to
be participants in the solicitation of proxies from the holders of
shares of HSAC common stock in respect of the Business Combination
described herein. Information about HSAC's directors and executive
officers and their ownership of HSAC common stock is set forth in
HSAC's preliminary proxy statement dated October 2, 2019 (the "Preliminary Proxy
Statement") filed with the Securities and Exchange Commission (the
"SEC"), as modified or supplemented by any Form 3 or Form 4 filed
with the SEC since the date of such filing. Other information
regarding the interests of the participants in the proxy
solicitation are included in the Preliminary Proxy Statement
pertaining to the Business Combination. These documents can be
obtained free of charge from the sources indicated below.
Additional Information and Where To Find It
In connection with the transaction described herein, HSAC has
filed and will file relevant materials with the SEC, including the
Preliminary Proxy Statement and a definitive proxy statement on
Schedule 14A. Promptly after filing its definitive proxy statement
with the SEC, HSAC will mail the definitive proxy statement and a
proxy card to each stockholder entitled to vote at the special
meeting relating to the transaction. INVESTORS AND SECURITY HOLDERS
OF HSAC ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS
OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN
CONNECTION WITH THE TRANSACTION THAT HSAC WILL FILE WITH THE SEC
WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT HSAC, IMMUNOVANT AND THE TRANSACTION. The
definitive proxy statement, the preliminary proxy statement and
other relevant materials in connection with the transaction (when
they become available), and any other documents filed by HSAC with
the SEC, may be obtained free of charge at the SEC's website
(www.sec.gov) or by writing to Health Sciences Acquisitions
Corporation, 412 West 15th Street, Floor 9, New York, NY 10011.
Contacts:
Sandeep Kulkarni, M.D.
Chief Operating Officer
Immunovant, Inc.
info@immunovant.com
Stephanie A. Sirota
Vice President of Corporate Strategy and Corporate
Communications
Health Sciences Acquisitions Corporation
hsac@rtwfunds.com
View original
content:http://www.prnewswire.com/news-releases/health-sciences-acquisitions-corporation-and-immunovant-to-host-joint-conference-call-for-the-investment-community-on-friday-october-11-at-830am-edt-300933446.html
SOURCE Health Sciences Acquisitions Corporation and
Immunovant